Known targets — ChEMBL curated mechanism
CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.40 |
| ▸ | CHRM1 known ✓ | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 known ✓ | P20309 | 6/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5990950 | 1.00 | CHRM2 (0.40) | CHRM2CHRM1PABPC1BLMCHRM3 | |
| Bromide SCHEMBL5993115 | 0.81 | CHRM3 (0.55) | CHRM2CHRM1PABPC1BLMCHRM3 | |
| Bromide SCHEMBL5993121 | 0.81 | CHRM3 (0.55) | CHRM2CHRM1PABPC1BLMCHRM3 | |
| SCHEMBL4477349 | 0.79 | CHRM3 (0.70) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4477348 | 0.79 | CHRM3 (0.70) | CHRM2CHRM1CHRM3 | |
| SCHEMBL9469983 | 0.76 | ACHE (0.39) | ALDH1A1 | |
| Bromide SCHEMBL4632234 | 0.76 | CHRM3 (0.57) | CHRM2CHRM1PABPC1BLMCHRM3 | |
| Bromide SCHEMBL4632228 | 0.76 | CHRM3 (0.57) | CHRM2CHRM1PABPC1BLMCHRM3 | |
| SCHEMBL138472 | 0.74 | CHRM3 (0.68) | CHRM2CHRM1PABPC1CHRM3SMN1; SMN2 | |
| SCHEMBL138471 | 0.74 | CHRM3 (0.68) | CHRM2CHRM1PABPC1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160844-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | claimed |
| US-20060160844-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160844-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | CHRM2 3/4885CHRM1 19/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.